Management of Borderline Resectable Pancreatic Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

趙玉沛 , 張太平

Corresponding?author：

Keywords：

胰腺癌; 交界性可切除; 新輔助治療; R0切除

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 趙玉沛,張太平. Management of Borderline Resectable Pancreatic Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2009, 16(8): 597-600. doi: Copy

1.	Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [J]. CA Cancer J Clin, 2008; 58(2): 71-96.
2.	Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies [J]. Ann Surg, 2006; 244(1): 10-15.
3.	Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience [J]. World J Surg, 2003; 27(3): 324-329.
4.	Carpelan-Holmstrm M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry [J]. Gut, 2005; 54(3): 385-387.
5.	Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience [J]. J Gastrointest Surg, 2006; 10(9): 1199-1211.
6.	Loos M, Kleeff J, Friess H, et al. Surgical treatment of pancreatic cancer [J]. Ann N Y Acad Sci, 2008; 1138: 169-180.
7.	Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100313 patients diagnosed from 1985-1995, using the National Cancer Database [J]. J Am Coll Surg, 1999; 189(1): 1-7.
8.	Katz MH, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma [J]. CA Cancer J Clin, 2008; 58(2): 111-125.
9.	National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Pancreatic Adenocarcinoma. http://www.nccn.org/professionals/physican_gls/default.asp. Accessed February 6, 2008.
10.	Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy [J]. Ann Surg Oncol, 2006; 13(8): 1035-1046.
11.	Parsons CM, Sutcliffe JL, Bold RJ. Preoperative evaluation of pancreatic adenocarcinoma [J]. J Hepatobiliary Pancreat Surg, 2008; 15(4): 429-435.
12.	Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT [J]. Abdom Imaging, 1996; 21(3): 202-206.
13.	Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT [J]. AJR Am J Roentgenol, 1997; 168(6): 1439-1443.
14.	Lall CG, Howard TJ, Skandarajah A, et al. New concepts in staging and treatment of locally advanced pancreatic head cancer [J]. AJR Am J Roentgenol, 2007; 189(5): 1044-1050.
15.	Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease [J]. J Am Coll Surg, 2008; 206(5): 833-848.
16.	Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis [J]. J Comput Assist Tomogr, 2005; 29(4): 438-445.
17.	Glenn J, Steinberg WM, Kurtzman SH, et al. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas [J]. J Clin Oncol, 1988; 6(3): 462-468.
18.	Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer [J]. Arch Surg, 2003; 138(9): 951-956.
19.	The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma [J]. Ann Surg, 1979; 189(2): 205-208.
20.	White R, Lee C, Anscher M, et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas [J]. Ann Surg Oncol, 1999; 6(1): 38-45.
21.	Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997; 15(6): 2403-2413.
22.	Shah AP, Strauss JB, Leslie WT, et al. Management of a patient with borderline resectable pancreatic cancer. Case report and review [J]. Oncology (Williston Park), 2008; 22(13): 1524-1529.
23.	Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head [J]. Br J Surg, 1998; 85(5): 611-617.
24.	Varadhachary GR. Current management of borderline-resectable pancreatic cancer [J]. Clin Adv Hematol Oncol, 2007; 5(10): 765-767.

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008 [J]. CA Cancer J Clin, 2008; 58(2): 71-96.
2. Cameron JL, Riall TS, Coleman J, et al. One thousand consecutive pancreaticoduodenectomies [J]. Ann Surg, 2006; 244(1): 10-15.
3. Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience [J]. World J Surg, 2003; 27(3): 324-329.
4. Carpelan-Holmstrm M, Nordling S, Pukkala E, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry [J]. Gut, 2005; 54(3): 385-387.
5. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience [J]. J Gastrointest Surg, 2006; 10(9): 1199-1211.
6. Loos M, Kleeff J, Friess H, et al. Surgical treatment of pancreatic cancer [J]. Ann N Y Acad Sci, 2008; 1138: 169-180.
7. Sener SF, Fremgen A, Menck HR, et al. Pancreatic cancer: a report of treatment and survival trends for 100313 patients diagnosed from 1985-1995, using the National Cancer Database [J]. J Am Coll Surg, 1999; 189(1): 1-7.
8. Katz MH, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma [J]. CA Cancer J Clin, 2008; 58(2): 111-125.
9. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Pancreatic Adenocarcinoma. http://www.nccn.org/professionals/physican_gls/default.asp. Accessed February 6, 2008.
10. Varadhachary GR, Tamm EP, Abbruzzese JL, et al. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy [J]. Ann Surg Oncol, 2006; 13(8): 1035-1046.
11. Parsons CM, Sutcliffe JL, Bold RJ. Preoperative evaluation of pancreatic adenocarcinoma [J]. J Hepatobiliary Pancreat Surg, 2008; 15(4): 429-435.
12. Loyer EM, David CL, Dubrow RA, et al. Vascular involvement in pancreatic adenocarcinoma: reassessment by thin-section CT [J]. Abdom Imaging, 1996; 21(3): 202-206.
13. Lu DS, Reber HA, Krasny RM, et al. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT [J]. AJR Am J Roentgenol, 1997; 168(6): 1439-1443.
14. Lall CG, Howard TJ, Skandarajah A, et al. New concepts in staging and treatment of locally advanced pancreatic head cancer [J]. AJR Am J Roentgenol, 2007; 189(5): 1044-1050.
15. Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease [J]. J Am Coll Surg, 2008; 206(5): 833-848.
16. Bipat S, Phoa SS, van Delden OM, et al. Ultrasonography, computed tomography and magnetic resonance imaging for diagnosis and determining resectability of pancreatic adenocarcinoma: a meta-analysis [J]. J Comput Assist Tomogr, 2005; 29(4): 438-445.
17. Glenn J, Steinberg WM, Kurtzman SH, et al. Evaluation of the utility of a radioimmunoassay for serum CA 19-9 levels in patients before and after treatment of carcinoma of the pancreas [J]. J Clin Oncol, 1988; 6(3): 462-468.
18. Schlieman MG, Ho HS, Bold RJ. Utility of tumor markers in determining resectability of pancreatic cancer [J]. Arch Surg, 2003; 138(9): 951-956.
19. The Gastrointestinal Tumor Study Group. A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma [J]. Ann Surg, 1979; 189(2): 205-208.
20. White R, Lee C, Anscher M, et al. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas [J]. Ann Surg Oncol, 1999; 6(1): 38-45.
21. Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial [J]. J Clin Oncol, 1997; 15(6): 2403-2413.
22. Shah AP, Strauss JB, Leslie WT, et al. Management of a patient with borderline resectable pancreatic cancer. Case report and review [J]. Oncology (Williston Park), 2008; 22(13): 1524-1529.
23. Leach SD, Lee JE, Charnsangavej C, et al. Survival following pancreaticoduodenectomy with resection of the superior mesenteric-portal vein confluence for adenocarcinoma of the pancreatic head [J]. Br J Surg, 1998; 85(5): 611-617.
24. Varadhachary GR. Current management of borderline-resectable pancreatic cancer [J]. Clin Adv Hematol Oncol, 2007; 5(10): 765-767.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Management of Borderline Resectable Pancreatic Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content